We started our cooperation on October 2020, when Billion To One was already backed by Y Combinator and had a working platform, to bring data management to the next level.
While introducing an innovative approach to genetic testing, Billion To One experienced issues with the speed of document management and error rates, and needed a vendor able to dig into the Django-based platform and transform their manual process into a streamlined digital flow.
Before starting our cooperation with Billion To One, we’ve already helped US healthcare companies like Haystack Intelligence and Surfacide, and had vast experience dealing with the US market specifics. To help Billion To One efficiently, we also obtained HIPAA certifications for every team member.
Since launching its first tests in 2020, BillionToOne has delivered advanced molecular diagnostics to 500,000+ patients.
By early 2025, the company surpassed 1 million UNITY prenatal tests conducted within five years.
Its annual UNITY test run-rate climbed above 500,000 tests per year in 2024, marking exponential operational growth.
By the end of 2024, UNITY held roughly 15% of the U.S. prenatal screening market, while Northstar oncology panels processed over 3,000 tests in Q4 2024 alone.
BillionToOne’s payer network expanded to cover 225 million+ insured lives across the United States.
The company has raised nearly $400 million in total funding as of late 2024, driving continued expansion in both prenatal and oncology diagnostics.
In 2024, BillionToOne reached $153 million in annual revenue, up from $72 million in 2023 — a 112% year-over-year increase — and achieved a 167% revenue CAGR between 2021 and 2024.